<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00433459</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000531687</org_study_id>
    <secondary_id>EURONET-PHL-C1</secondary_id>
    <secondary_id>EU-20703</secondary_id>
    <secondary_id>EUDRACT-2006-000995-33</secondary_id>
    <secondary_id>CCLG-HD-2007-10</secondary_id>
    <nct_id>NCT00433459</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma</brief_title>
  <official_title>First International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christine Mauz-Körholz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Krebshilfe e.V., Bonn (Germany)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Euronet Worldwide</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Martin-Luther-Universität Halle-Wittenberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer&#xD;
      cells, either by killing the cells or by stopping them from dividing. Giving more than one&#xD;
      drug (combination chemotherapy) may kill more cancer cells. It is not yet known which&#xD;
      combination chemotherapy regimen is more effective in treating Hodgkin's lymphoma.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying different combination chemotherapy&#xD;
      regimens to compare how well they work in treating young patients with Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine whether the 5-year event-free survival (EFS) rate in pediatric patients with&#xD;
           Hodgkin's lymphoma with an adequate response after 2 courses of vincristine, etoposide,&#xD;
           prednisone, and doxorubicin hydrochloride (OEPA) (without radiotherapy) are consistent&#xD;
           with an estimated target EFS rate of 90%.&#xD;
&#xD;
        -  Compare the EFS (without a deterioration) of patients treated with procarbazine&#xD;
           hydrochloride vs dacarbazine (treatment groups 2 and 3).&#xD;
&#xD;
        -  Determine the treatment outcome of a standardized risk-adapted relapse strategy in these&#xD;
           patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine whether the 5-year EFS rate in patients with Hodgkin's lymphoma with an&#xD;
           inadequate response after 2 OEPA courses and standard involved-field radiotherapy are&#xD;
           consistent with an estimated target EFS rate of 90%.&#xD;
&#xD;
        -  Determine whether a positive positron emission tomography scan before planned high-dose&#xD;
           chemotherapy with autologous stem cell transplantation has a negative prognostic&#xD;
           significance.&#xD;
&#xD;
        -  Compare the effect of dacarbazine vs procarbazine on the rate of infertility in males&#xD;
           and premature menopause in females (treatment groups 2 and 3).&#xD;
&#xD;
      Tertiary&#xD;
&#xD;
        -  Determine the impact of real-time central staging and response assessment on treatment&#xD;
           outcome in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, controlled, parallel-group, open-label, multicenter study.&#xD;
      Patients are stratified according to staging and response assessment (central vs local) and&#xD;
      disease stage (IA/B or IIA [first-line treatment group 1] vs I_EA/B, II_EA, IIB, or IIIA&#xD;
      [first-line treatment group 2] vs II_EB, III_E A/B, IIIB, or IVA/B [first-line treatment&#xD;
      group 3]).&#xD;
&#xD;
        -  First-line treatment group 1: Patients receive oral prednisone (or prednisolone) 3 times&#xD;
           daily on days 1-15, vincristine IV on days 1, 8, and 15, doxorubicin hydrochloride IV&#xD;
           over 1-6 hours on days 1 and 15, and etoposide (or etoposide phosphate) IV over 1-2&#xD;
           hours on days 1-5 (OEPA).&#xD;
&#xD;
      Treatment repeats every 28 days for 2 courses in the absence of unacceptable toxicity.&#xD;
      Patients are assessed by fludeoxyglucose F 18 positron emission tomography (^18FDG-PET) scan.&#xD;
      Patients with inadequate response undergo radiotherapy within 35 days after completion of&#xD;
      OEPA.&#xD;
&#xD;
        -  First-line treatment group 2: Patients receive OEPA as in group 1. After completion of&#xD;
           OEPA, patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
             -  Arm I: Patients receive oral prednisone (or prednisolone) 3 times daily and oral&#xD;
                procarbazine hydrochloride 2-3 times a day on days 1-15 and vincristine IV and&#xD;
                cyclophosphamide IV over 1 hour on days 1 and 8 (COPP).&#xD;
&#xD;
             -  Arm II: Patients receive oral prednisone (or prednisolone) 3 times daily on days&#xD;
                1-15, dacarbazine IV over 15-30 minutes on days 1-3, and vincristine IV and&#xD;
                cyclophosphamide IV over 1 hour on days 1 and 8 (COPDAC).&#xD;
&#xD;
      In both arms, treatment repeats every 28 days for 2 courses in the absence of unacceptable&#xD;
      toxicity. Patients are assessed by ^18FDG-PET scan. Patients with an inadequate response&#xD;
      undergo radiotherapy within 35 days after completion of COPP or COPDAC.&#xD;
&#xD;
        -  First-line treatment group 3: Patients receive OEPA as in group 1. After completion of&#xD;
           OEPA, patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
             -  Arm I: Patients receive COPP as in arm I of group 2.&#xD;
&#xD;
             -  Arm II: Patients receive COPDAC as in arm II of group 2. In both arms, treatment&#xD;
                repeats every 28 days for 4 courses in the absence of unacceptable toxicity.&#xD;
                Patients are assessed by ^18FDG-PET scan. Patients with an inadequate response&#xD;
                undergo radiotherapy within 35 days after completion of COPP or COPDAC.&#xD;
&#xD;
      Patients with biopsy-confirmed disease progression OR relapse after first-line treatment on&#xD;
      this study or on protocols DAL-HD 90, GPOH-HD 95, GPOHHD 2002 Pilot, or similar treatment&#xD;
      proceed to second-line therapy. Patients are stratified according to relapse/progression&#xD;
      status (late relapse from first-line treatment group 1 [second-line treatment group 1] vs&#xD;
      early relapse from first-line treatment groups 1, 2, or 3 or late relapse from first-line&#xD;
      treatment groups 2 or 3 [second-line treatment group 2] vs disease progression [second-line&#xD;
      treatment group 3]). Patients undergo a ^18FDG-PET scan prior to beginning second-line&#xD;
      therapy.&#xD;
&#xD;
        -  Second-line treatment group 1: Patients receive ifosfamide IV over 22 hours and&#xD;
           etoposide IV over 1-2 hours and oral prednisone three times daily on days 1-5 (IEP).&#xD;
           Patients then receive doxorubicin hydrochloride IV over 1-6 hours, bleomycin IV,&#xD;
           vinblastine IV, and dacarbazine IV over 15-30 minutes on days 22 and 36 (ABVD).&#xD;
           Treatment repeats every 50 days for 2 courses in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      After chemotherapy treatment, patients undergo radiotherapy.&#xD;
&#xD;
        -  Second-line treatment group 2: Patients receive IEP and ABVD as in group 1. Autologous&#xD;
           stem cells are collected after course 1 or 2 of IEP/ABVD.&#xD;
&#xD;
      After chemotherapy, patients with an adequate response undergo radiotherapy. Patients with an&#xD;
      inadequate response undergo high-dose chemotherapy comprising carmustine IV over 1-2 hours on&#xD;
      day -7, etoposide IV and cytarabine IV over 30 minutes twice daily on days -6 to -3, and&#xD;
      melphalan IV over 1½ hours on day -2. Patients then undergo autologous hematopoietic stem&#xD;
      cell transplantation (HSCT).&#xD;
&#xD;
      Patients undergo a ^18FDG-PET scan on day 50-54. Patients with ^18FDG-PET scan positive&#xD;
      disease undergo radiotherapy.&#xD;
&#xD;
        -  Second-line treatment group 3: Patients receive IEP and ABVD as in group 1. All patients&#xD;
           then undergo high-dose chemotherapy and HSCT as in group 2.&#xD;
&#xD;
      Patients undergo a ^18FDG-PET scan on day 50-54. Patients with ^18FDG-PET scan positive&#xD;
      disease undergo radiotherapy.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 2,150 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTC (Common toxicity criteria) toxicity levels of therapy elements</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of male infertility score</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of female infertility score</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term consequences (e.g., premature menopause, secondary cancer)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2134</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>COPP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>procarbazine-containing consolidation chemotherapy arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPDAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>procarbazine-free consolidation chemotherapy arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>drug is used in first line treatment in combination (COPP or COPDAC)</description>
    <arm_group_label>COPDAC</arm_group_label>
    <arm_group_label>COPP</arm_group_label>
    <other_name>CYC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dacarbazine</intervention_name>
    <description>drug is used in first line treatment in combination (COPDAC)</description>
    <arm_group_label>COPDAC</arm_group_label>
    <other_name>DTIC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
    <description>drug is used in first line treatment in combination (OEPA, COPP or COPDAC)</description>
    <arm_group_label>COPDAC</arm_group_label>
    <arm_group_label>COPP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>drug is used in first line treatment in combination (OEPA, COPP or COPDAC)</description>
    <arm_group_label>COPDAC</arm_group_label>
    <arm_group_label>COPP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>procarbazine hydrochloride</intervention_name>
    <description>drug is used in first line treatment in combination (COPP)</description>
    <arm_group_label>COPP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>drug is used in first line treatment in combination (OEPA, COPP or COPDAC)</description>
    <arm_group_label>COPDAC</arm_group_label>
    <arm_group_label>COPP</arm_group_label>
    <other_name>VCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fludeoxyglucose F 18</intervention_name>
    <description>used as a diagnostic marker for metabolically active tumour at staging and response assessment</description>
    <arm_group_label>COPDAC</arm_group_label>
    <arm_group_label>COPP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>part of combination treatment (combined modality between chemo- and radiotherapy)</description>
    <arm_group_label>COPDAC</arm_group_label>
    <arm_group_label>COPP</arm_group_label>
    <other_name>IFRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed classical Hodgkin's lymphoma&#xD;
&#xD;
               -  No lymphocyte-predominant Hodgkin's lymphoma&#xD;
&#xD;
               -  Fine-needle biopsy not sufficient&#xD;
&#xD;
          -  No prior treatment for Hodgkin's lymphoma except for recommended pre-phase therapy for&#xD;
             a large mediastinal tumor&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  No known hypersensitivity or contraindication to study drugs&#xD;
&#xD;
          -  No other current malignancy&#xD;
&#xD;
          -  No severe concurrent disease (e.g., immune deficiency syndrome)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for up to 1 year after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy&#xD;
&#xD;
          -  At least 30 days since prior and no other concurrent investigational drugs or&#xD;
             participation in another investigational trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dieter Koerholz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Martin-Luther-Universität Halle-Wittenberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>W. Hamish Wallace, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Judith Landman-Parker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital d'Enfants Trousseau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitaetsklinikum Giessen-Marburg</name>
      <address>
        <city>Giessen</city>
        <zip>D-35385</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH9 1LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?a=8&amp;id=NCI-2014-02026&amp;loc=0&amp;rl=2&amp;st=C7258&amp;t=C9357</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQ® database</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 8, 2007</study_first_submitted>
  <study_first_submitted_qc>February 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2007</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Martin-Luther-Universität Halle-Wittenberg</investigator_affiliation>
    <investigator_full_name>Christine Mauz-Körholz</investigator_full_name>
    <investigator_title>Prof. Dr. med. Christine Mauz-Körholz</investigator_title>
  </responsible_party>
  <keyword>childhood lymphocyte depletion Hodgkin lymphoma</keyword>
  <keyword>childhood mixed cellularity Hodgkin lymphoma</keyword>
  <keyword>childhood nodular sclerosis Hodgkin lymphoma</keyword>
  <keyword>stage I childhood Hodgkin lymphoma</keyword>
  <keyword>stage II childhood Hodgkin lymphoma</keyword>
  <keyword>stage III childhood Hodgkin lymphoma</keyword>
  <keyword>stage IV childhood Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Procarbazine</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

